A randomised controlled trial to evaluate the effectiveness of a smoking cessation intervention for people with chronic hepatitis C

Not Applicable

Recruiting

• Conditions: icotine dependence; Depression; Anxiety; Stress; Nicotine dependence; Mental Health - Addiction; Public Health - Health promotion/education

• Registration Number: ACTRN12611000346976
• Lead Sponsor: Royal Brisbane and Women's Hospital (RBWH)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-04-04
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 132

Inclusion Criteria

The study will include people who visit the hepatology outpatient’s clinics RBWH, for management of chronic hepatitis-C disease.

Inclusion Criteria
adults over the age of 18 years
who smoke cigarettes
who attend the hepatology outpatients clinics at the Royal Brisbane & Women's Hospital for the management of chronic hepatitis-C.

Exclusion Criteria

1. People who are currently undergoing interferon based treatment will be excluded from the study as symptoms from treatment may confound the health outcomes being measured in the project.
2. People who are currently undergoing a smoking cessation programme will be excluded
3.Occassional smokers are excluded as it is not recommended they use nicotine replacement therapy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Compliance with Smoking Cessation/reduction as measured by a self report smoking diary and Fagerstrom Tolerance Questionnaire[This Time 1: baseline prior to randomisation<br>Time 2: after 6 weeks<br>Time 3: after 12 weeks]

Secondary Outcome Measures

Name	Time	Method
Reduced Nicotine addiction measured by Fagerstrom Test for NicotineDependence[Time 1: baseline prior to randomisation<br>Time 2: after 6 weeks<br>Time 3: after 12 weeks];Change in levels of Depression, Anxiety and Stress as measured by Depression, Anxiety and Stress Scale (DASS 21)[Time 1: baseline prior to randomisation<br>Time 2: after 6 weeks<br>Time 3: after 12 weeks];Quality of Life as measured by WHOQOLBREF (Quality of Life questionnaire),[Time 1: baseline prior to randomisation<br>Time 2: after 6 weeks<br>Time 3: after 12 weeks]